摘要
作为一种重要的转录后修饰,组蛋白去乙酰化在染色质重塑和基因表达中起着重要作用。 组蛋白去乙酰化的异常修饰会导致各种疾病。 作为组蛋白去乙酰化酶 (HDAC) 的关键成员,HDAC6 在许多生理过程中充当关键调节剂。 HDAC6 的异常表达会导致癌症、神经变性和其他疾病。 在这里,我们回顾了 HDAC6 选择性抑制剂的生理学、蛋白质结构和开发方面的最新进展。
关键词: 转录后修饰,HDAC6,结构,癌症,选择性抑制剂,组蛋白去乙酰化。
Current Medicinal Chemistry
Title:Recent Development of Novel HDAC6 Isoform-selective Inhibitors
Volume: 28 Issue: 21
关键词: 转录后修饰,HDAC6,结构,癌症,选择性抑制剂,组蛋白去乙酰化。
摘要: As an important post-transcription modification, histone deacetylation plays significant roles in chromatin remodeling and gene expression. The aberrant modification of histone deacetylation leads to various diseases. As a critical member of histone deacetylase (HDAC), HDAC6 serves as a key modulator in many physiological processes. Abnormal expression of HDAC6 gives rise to cancer, neurodegeneration and other diseases. Here, we have reviewed recent advances in physiological, protein structure and development of HDAC6 selective inhibitors.
Export Options
About this article
Cite this article as:
Recent Development of Novel HDAC6 Isoform-selective Inhibitors, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867327666201111142653
DOI https://dx.doi.org/10.2174/0929867327666201111142653 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia
Current Gene Therapy Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry Editorial (Thematic issue: Discovering New Anticancer Activities from Old Drugs)
Current Medicinal Chemistry Editorial [Hot Topic: Interferon Alpha2 in the Treatment of Hematological Malignancies. Status and Perspectives (Guest Editor: Hans Carl Hasselbalch)]
Current Drug Targets Improvement of Adoptive Cellular Immunotherapy of Human Cancer Using Ex-Vivo Gene Transfer
Current Gene Therapy Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design Targeting Autophagic Pathways by Plant Natural Compounds in Cancer Treatment
Current Drug Targets SALL4: Engine of Cell Stemness
Current Gene Therapy STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Antiangiogenic Therapy
Current Pharmaceutical Design Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Hck Inhibitors as Potential Therapeutic Agents in Cancer and HIV Infection
Current Medicinal Chemistry Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma
Current Signal Transduction Therapy Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine